PharmAla Contracts with Partner to Act as US Distributor
March 24, 2025 09:00 ET
|
PharmAla Biotech
PharmAla sidesteps tariff risk and expands clinical operations in the United States by contracting with Sharp Clinical Services as distribution partner
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
March 21, 2025 09:00 ET
|
PharmAla Biotech
PharmAla completes shipment of MDMA to University of Washington, to be used in a Narcissism clinical trial. It also appoints Ali Taghva as CCO.
PharmAla Completes Shipment of LaNeo™ MDMA to UCLA for Schizophrenia Study
March 03, 2025 09:01 ET
|
PharmAla Biotech
PharmAla completes historic first shipment of MDMA from Canada to USA for use in a UCLA Clinical Trial
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
February 27, 2025 14:45 ET
|
PharmAla Biotech
PharmAla to supply the STRONG STAR Consortium with new 20mg MDMA dose to treat active-duty military personnel in a clinical trial
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
January 20, 2025 08:55 ET
|
PharmAla Biotech
PharmAla partners with Merhavim and MAPS Israel for innovative MDMA PTSD clinical trial data sharing partnership in wake of Gaza Ceasefire
PharmAla Announces Private Placement
December 13, 2024 09:25 ET
|
PharmAla Biotech
PharmAla announces private placement financing
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
October 21, 2024 09:25 ET
|
PharmAla Biotech
PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.
Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial
September 14, 2023 14:59 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased...